[go: up one dir, main page]

WO1998017810A3 - Multi-functional chimeric hematopoietic receptor agonists - Google Patents

Multi-functional chimeric hematopoietic receptor agonists Download PDF

Info

Publication number
WO1998017810A3
WO1998017810A3 PCT/US1997/020037 US9720037W WO9817810A3 WO 1998017810 A3 WO1998017810 A3 WO 1998017810A3 US 9720037 W US9720037 W US 9720037W WO 9817810 A3 WO9817810 A3 WO 9817810A3
Authority
WO
WIPO (PCT)
Prior art keywords
functional chimeric
hematopoietic receptor
chimeric hematopoietic
receptor agonists
receptor agonist
Prior art date
Application number
PCT/US1997/020037
Other languages
French (fr)
Other versions
WO1998017810A2 (en
Inventor
Wherter Charles A Mc
Yiqing Feng
Kearn John P Mc
Neena L Summers
Nicholas R Staten
Philip R Streeter
John C Minnerly
Nancy I Minster
Susan L Woulfe
Original Assignee
Searle & Co
Wherter Charles A Mc
Yiqing Feng
Kearn John P Mc
Neena L Summers
Nicholas R Staten
Philip R Streeter
John C Minnerly
Nancy I Minster
Susan L Woulfe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co, Wherter Charles A Mc, Yiqing Feng, Kearn John P Mc, Neena L Summers, Nicholas R Staten, Philip R Streeter, John C Minnerly, Nancy I Minster, Susan L Woulfe filed Critical Searle & Co
Priority to EP97946495A priority Critical patent/EP0935663A2/en
Priority to AU51652/98A priority patent/AU725547B2/en
Priority to BR9713668-9A priority patent/BR9713668A/en
Priority to IL12956597A priority patent/IL129565A0/en
Priority to NZ335382A priority patent/NZ335382A/en
Priority to RO99-00480A priority patent/RO120919B1/en
Priority to CA002268742A priority patent/CA2268742A1/en
Priority to JP51975498A priority patent/JP2001504689A/en
Publication of WO1998017810A2 publication Critical patent/WO1998017810A2/en
Publication of WO1998017810A3 publication Critical patent/WO1998017810A3/en
Priority to NO991948A priority patent/NO991948L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proteins and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.
PCT/US1997/020037 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists WO1998017810A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP97946495A EP0935663A2 (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists
AU51652/98A AU725547B2 (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists
BR9713668-9A BR9713668A (en) 1996-10-25 1997-10-23 Multifunctional chimeric hematopoietic receptor agonists
IL12956597A IL129565A0 (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists
NZ335382A NZ335382A (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic polypeptides of IL-3, GCSF, Flt3L, EPO, stem cell factor, cmpl link with or without linker group consisting of Alanine, Glycine and/or Serine for treating autoimmune and tumour related diseases
RO99-00480A RO120919B1 (en) 1996-10-25 1997-10-23 Hematopoietic protein, nucleic acid molecule encoding the same, pharmaceutical composition and use of said protein
CA002268742A CA2268742A1 (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists
JP51975498A JP2001504689A (en) 1996-10-25 1997-10-23 Multifunctional chimeric hematopoietic receptor agonist
NO991948A NO991948L (en) 1996-10-25 1999-04-23 Multifunctional chimeric hematopoietic receptor agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2962996P 1996-10-25 1996-10-25
US60/029,629 1996-10-25

Publications (2)

Publication Number Publication Date
WO1998017810A2 WO1998017810A2 (en) 1998-04-30
WO1998017810A3 true WO1998017810A3 (en) 1998-10-15

Family

ID=21850035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020037 WO1998017810A2 (en) 1996-10-25 1997-10-23 Multi-functional chimeric hematopoietic receptor agonists

Country Status (17)

Country Link
EP (1) EP0935663A2 (en)
JP (1) JP2001504689A (en)
KR (1) KR100497423B1 (en)
AR (1) AR010041A1 (en)
AU (1) AU725547B2 (en)
BR (1) BR9713668A (en)
CA (1) CA2268742A1 (en)
CZ (1) CZ295843B6 (en)
IL (1) IL129565A0 (en)
NO (1) NO991948L (en)
NZ (1) NZ335382A (en)
PL (1) PL333023A1 (en)
RO (1) RO120919B1 (en)
RU (2) RU2245887C2 (en)
TW (2) TW200413407A (en)
WO (1) WO1998017810A2 (en)
ZA (1) ZA979607B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998046750A1 (en) * 1997-04-11 1998-10-22 G.D. Searle & Co. flt3 LIGAND CHIMERIC PROTEINS
BR9905867A (en) * 1998-11-06 2001-01-23 Bio Sidus S A Recombinant human erythropoietin-producing cell line and the recombinant human erythropoietin produced by this cell
WO2002101047A1 (en) * 2001-06-12 2002-12-19 Smithkline Beecham Corporation Method of identifying compounds that modulate epo primary response gene 1, eprg1, activities
BR0211071A (en) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Polypeptide conjugate showing g-csf activity, method for preparing a g-csf conjugate, composition, method for treating a mammal suffering from an insufficient neutrophilic level, and use of the polypeptide conjugate
ATE447611T1 (en) 2003-08-18 2009-11-15 Univ California POLYPEPTIDE DISPLAY LIBRARIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
DE602006020562D1 (en) 2005-06-01 2011-04-21 Maxygen Inc HREN FOR THIS
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7666817B2 (en) 2005-08-31 2010-02-23 The Regents Of The University Of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
WO2007098548A1 (en) * 2006-03-01 2007-09-07 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
JP7749186B2 (en) * 2019-03-28 2025-10-06 オリオニス バイオサイエンシズ，インコーポレイテッド FMS-like tyrosine kinase 3 ligand (FLT3L)-based chimeric proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
WO1995021197A1 (en) * 1994-02-04 1995-08-10 G.D. Searle & Co. Il-3 variant hematopoiesis fusion protein
WO1995021254A1 (en) * 1994-02-04 1995-08-10 G. D. Searle & Co. Multivariant il-3 hematopoiesis fusion protein
WO1995027732A2 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006116A1 (en) * 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
WO1995021197A1 (en) * 1994-02-04 1995-08-10 G.D. Searle & Co. Il-3 variant hematopoiesis fusion protein
WO1995021254A1 (en) * 1994-02-04 1995-08-10 G. D. Searle & Co. Multivariant il-3 hematopoiesis fusion protein
WO1995027732A2 (en) * 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Circularly permuted ligands and circularly permuted chimeric molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORLICK, R.A. ET AL.: "Permuteins of interleukin 1beta ...", PROTEIN ENGINEERING, vol. 5, no. 5, 1992, pages 427 - 431, XP002022097 *

Also Published As

Publication number Publication date
KR100497423B1 (en) 2005-07-07
AU725547B2 (en) 2000-10-12
KR20000052812A (en) 2000-08-25
AR010041A1 (en) 2000-05-17
RO120919B1 (en) 2006-09-29
CA2268742A1 (en) 1998-04-30
AU5165298A (en) 1998-05-15
EP0935663A2 (en) 1999-08-18
PL333023A1 (en) 1999-11-08
IL129565A0 (en) 2000-02-29
BR9713668A (en) 2000-03-08
RU2245887C2 (en) 2005-02-10
CZ295843B6 (en) 2005-11-16
NO991948L (en) 1999-06-23
WO1998017810A2 (en) 1998-04-30
JP2001504689A (en) 2001-04-10
CZ132399A3 (en) 1999-12-15
RU2005105360A (en) 2006-08-10
ZA979607B (en) 1999-04-28
NO991948D0 (en) 1999-04-23
TW200413407A (en) 2004-08-01
NZ335382A (en) 2001-03-30
TW591035B (en) 2004-06-11

Similar Documents

Publication Publication Date Title
ZA9711239B (en) OB fusion protein compositions and methods.
CA2200423A1 (en) Novel estrogen receptor
WO1998017810A3 (en) Multi-functional chimeric hematopoietic receptor agonists
AU8784498A (en) Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU9386398A (en) Cysteine rich receptors: trail
AU3945197A (en) Novel stable liquid paracetamol compositions, and method for preparing same
AU3633997A (en) Chemokine receptor antagonists
EP0825260A3 (en) Arginase II
WO1997012985A3 (en) Multi-functional hematopoietic receptor agonists
EP1117692A4 (en) Tie2 agonist antibodies
WO2000005367A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
PL336470A1 (en) Mammalian cytokin-like factor 7
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
WO2000015798A3 (en) Mammalian transforming growth factor beta - 9 (ztgfss9)
WO2000029448A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
AU4243097A (en) Mammalian chemokines, related reagents
AU1178100A (en) Novel g protein-coupled receptor protein, its dna and ligand thereof
AU2813297A (en) Mammalian mixed lymphocyte receptors, chemokine receptors {mmlr-ccr}
AU9512298A (en) Beta3-adrenoreceptor agonists, agonist compositions and methods of using
IL128500A0 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta (b) benzofurans
WO1999009182A3 (en) Rab proteins
WO1998024896A3 (en) Muteins of obese protein
WO1999029720A3 (en) Mammalian alpha helical protein-1
AU8552198A (en) 2-aryl-2,5-dihydro-pyrazolo{4,3-c}quinolin-3-ones as gaba alpha 5 receptor inverse agonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180892.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 51652/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV1999-1323

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2268742

Country of ref document: CA

Ref document number: 2268742

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997946495

Country of ref document: EP

Ref document number: 335382

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1998 519754

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003877

Country of ref document: MX

Ref document number: 1019997003635

Country of ref document: KR

Ref document number: 99-00480

Country of ref document: RO

WWP Wipo information: published in national office

Ref document number: 1997946495

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-1323

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997003635

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 51652/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1019997003635

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV1999-1323

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1997946495

Country of ref document: EP